REaCT: REthinking Clinical Trials

REaCT-HER TIME

REaCT-HER TIME	Evaluating 6-months of herceptin in patients with HER2 positive early-stage breast cancer Principal Investigator(s): Dr. Sharon McGee
ClinicalTrials.gov: NCT04928261
Patients with HER2 positive breast cancer that were treated with chemotherapy and HER2 targeted therapy (such as Herceptin ®) before breast surgery, with no evidence of any remaining cancer at the time of surgery, are considered to have a low risk cancer. This single arm study will evaluate patient follow up data, cardiac monitoring and quality of life to determine if a shorter course of HER2 targeted therapy is acceptable in this low risk patient population.
Sites: The Ottawa Hospital
Tags: Early stage Breast Cancer
Publications: Survey: Shorter durations of anti-HER2 therapy for patients with early-stage, HER2-positive breast cancer: the physician perspective. Bradbury et al, 2023. PMID:38132397